MX2025011902A - Compuestos de derivados de acido indazol propionico sustituidos con indazol y usos de estos como activadores de ampk - Google Patents

Compuestos de derivados de acido indazol propionico sustituidos con indazol y usos de estos como activadores de ampk

Info

Publication number
MX2025011902A
MX2025011902A MX2025011902A MX2025011902A MX2025011902A MX 2025011902 A MX2025011902 A MX 2025011902A MX 2025011902 A MX2025011902 A MX 2025011902A MX 2025011902 A MX2025011902 A MX 2025011902A MX 2025011902 A MX2025011902 A MX 2025011902A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
propionic acid
tautomers
acceptable salts
substituted indazole
Prior art date
Application number
MX2025011902A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Keefe Cameron Kimberly O'
Edward Lee Conn
David Christopher Ebner
Dilinie Prasadhini Fernando
Kevin James Filipski
Brian Stephen Gerstenberger
Chan Woo Huh
Daniel Wei- Shung Kung
Esther Cheng Yin Lee
Alan Martin Mathiowetz
Sarah Jane Mear
Jessica Gloria Katherine O'brien
Aaron Christopher Smith
Meihua Mike Tu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2025011902A publication Critical patent/MX2025011902A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere a derivados de ácido indazol propiónico sustituidos, sales aceptables desde el punto de vista farmacéutico, tautómeros o sales aceptables desde el punto de vista farmacéutico de los tautómeros de estos que pueden activar la proteína quinasa activada por adenosina 5'-monofosfato (AMPK). La invención se refiere además a composiciones farmacéuticas que comprenden derivados de ácido indazol propiónico sustituidos activadores de AMPK, sales aceptables desde el punto de vista farmacéutico, tautómeros o sales aceptables desde el punto de vista farmacéutico de los tautómeros de estos y al menos un excipiente aceptable desde el punto de vista farmacéutico, y métodos para tratar una afección que comprende administrar derivados de ácido indazol propiónico sustituidos activadores de AMPK, sales aceptables desde el punto de vista farmacéutico, tautómeros, o sales aceptables desde el punto de vista farmacéutico de los tautómeros de estos.
MX2025011902A 2023-04-06 2025-10-03 Compuestos de derivados de acido indazol propionico sustituidos con indazol y usos de estos como activadores de ampk MX2025011902A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363494598P 2023-04-06 2023-04-06
PCT/IB2024/053239 WO2024209363A1 (en) 2023-04-06 2024-04-03 Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Publications (1)

Publication Number Publication Date
MX2025011902A true MX2025011902A (es) 2025-11-03

Family

ID=90721385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025011902A MX2025011902A (es) 2023-04-06 2025-10-03 Compuestos de derivados de acido indazol propionico sustituidos con indazol y usos de estos como activadores de ampk

Country Status (15)

Country Link
US (1) US20240336572A1 (es)
EP (1) EP4688750A1 (es)
JP (1) JP2026515644A (es)
KR (1) KR20250164854A (es)
CN (1) CN121039104A (es)
AR (1) AR132329A1 (es)
AU (1) AU2024249981A1 (es)
CO (1) CO2025013813A2 (es)
CR (1) CR20250419A (es)
DO (1) DOP2025000253A (es)
IL (1) IL323522A (es)
MX (1) MX2025011902A (es)
PE (1) PE20260010A1 (es)
TW (1) TWI899933B (es)
WO (1) WO2024209363A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024209363A1 (en) * 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
WO2026074467A1 (en) * 2024-10-04 2026-04-09 Pfizer Inc. Extended release formulations comprising substituted indazole propionic acid derivative compounds and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0578850A1 (en) 1992-07-17 1994-01-19 Biogal Gyogyszergyar Process for the preparation of carboxylic acids and derivatives of them
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
EP2242757B1 (en) 2008-01-09 2012-08-01 Array Biopharma, Inc. Pyrazolopyridines as kinase inhibitors
WO2009149837A1 (en) 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof
CA2767233A1 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
WO2012119046A2 (en) 2011-03-02 2012-09-07 Bioenergenix Heterocyclic compounds for the inhibition of pask
EP2694509B1 (en) 2011-04-05 2016-05-18 Pfizer Limited Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
US8889730B2 (en) * 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014049133A1 (en) 2012-09-28 2014-04-03 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
JP6441830B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンcの置換2−アザ−ビシクロ[2.2.1]ヘプタン−3−カルボン酸(シアノ−メチル)−アミド阻害剤
EP3417851B1 (en) 2013-09-09 2020-07-22 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
WO2016004305A2 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
KR20160030001A (ko) 2014-09-05 2016-03-16 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CA2969164A1 (en) 2014-12-23 2016-06-30 Genfit Heterocyclic derivatives as rorgamma modulators
WO2016115360A1 (en) 2015-01-14 2016-07-21 Coferon, Inc. C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same
CN108299425B (zh) 2015-03-24 2020-09-18 上海璎黎药业有限公司 稠环衍生物、其制备方法、中间体、药物组合物及应用
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018229543A2 (en) 2017-06-14 2018-12-20 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
CN112020496B (zh) 2018-04-18 2023-04-28 南京明德新药研发有限公司 作为rho激酶抑制剂的苯并吡唑类化合物
EP3787612A4 (en) 2018-05-04 2021-11-17 Remedy Plan, Inc. CANCER TREATMENTS AGAINST CANCER STEM CELLS
EP3813784B1 (en) 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith
JP7511564B2 (ja) * 2018-12-31 2024-07-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリア機能不全を治療する方法及び配合物
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
KR102873783B1 (ko) 2019-02-25 2025-10-21 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 Jak 억제제 화합물 및 그 사용
MX2022014505A (es) * 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
JP2023553835A (ja) 2020-12-17 2023-12-26 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大環状化合物およびそれらの使用
WO2022150574A1 (en) 2021-01-08 2022-07-14 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
WO2022204150A1 (en) 2021-03-22 2022-09-29 Blue Oak Pharmaceuticals, Inc. Compounds and compositions for treating cns disorders
TW202304890A (zh) 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2023091707A1 (en) 2021-11-19 2023-05-25 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of jak and methods of use
CN119013256A (zh) * 2022-01-25 2024-11-22 Evvia治疗公司 Ampk激动剂及其使用方法
EP4504722A4 (en) 2022-04-04 2026-03-18 Brenig Therapeutics Inc LRRK2 INHIBITORS
WO2024209363A1 (en) * 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Also Published As

Publication number Publication date
AU2024249981A1 (en) 2025-10-16
EP4688750A1 (en) 2026-02-11
TWI899933B (zh) 2025-10-01
CN121039104A (zh) 2025-11-28
CO2025013813A2 (es) 2025-10-20
US20240336572A1 (en) 2024-10-10
CR20250419A (es) 2025-10-07
AR132329A1 (es) 2025-06-18
TW202448861A (zh) 2024-12-16
IL323522A (en) 2025-11-01
KR20250164854A (ko) 2025-11-25
JP2026515644A (ja) 2026-05-19
DOP2025000253A (es) 2025-11-30
PE20260010A1 (es) 2026-01-06
WO2024209363A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
PH12022552745A1 (en) [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
PH12023550130A1 (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
PH12022550783A1 (en) Antiviral heterocyclic compounds
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
BR0113448A (pt) Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase
NO20084997L (no) Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MX2023009961A (es) Compuestos heterociclicos antivirales.
MX2024012335A (es) Compuestos heterociclicos antivirales
CO2025013813A2 (es) Compuestos derivados de ácido indazolpropiónico sustituidos y usos de los mismos como activadores de ampk
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2025011346A (es) Compuestos de quinolinona amida y usos de los mismos
MX2025002790A (es) Derivados de piperidina 2-sustituidos, metodos de preparacion y usos medicinales de los mismos
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MD523G2 (ro) Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
MX2023014547A (es) Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3).
JOP20240258A1 (ar) مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها
AU2021326530A8 (en) Dosage form compositions comprising an inhibitor of btk and mutants thereof
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
AU2021260669A8 (en) A formulation for treating ophthalmic conditions